• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Corium Pharma Solutions Names Ernie De Paolantonio as Chief Financial Officer

    2/15/23 8:00:00 AM ET
    $AGRX
    $PG
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Package Goods/Cosmetics
    Consumer Discretionary
    Get the next $AGRX alert in real time by email

    Appointment of Ernie De Paolantonio to Chief Financial Officer Further Strengthens Leadership Team

    GRAND RAPIDS, Mich., Feb. 15, 2023 /PRNewswire/ -- Corium Pharma Solutions, Inc. (CPSI), a leading, full-service contract development and manufacturing organization specializing in novel drug delivery technologies for prescription drug and consumer products including transdermal modalities, has named Ernie De Paolantonio as Chief Financial Officer. This announcement follows the recent appointments of several industry veterans, Mark Sirgo as Chief Executive Officer, Kevin Ostrander as Chief Business Officer and Dr. Niraj Vasisht as Chief Technology Officer.

    Appointment of Ernie De Paloantonio to Chief Financial Officer Further Strengthens CPSI's Leadership Team

    Ernie brings over 30 years of financial and business experience in the pharmaceutical industry including both private and public commercial and manufacturing companies. Most recently, he was Chief Financial Officer of Journey Medical Corporation, a commercial stage dermatology company. Prior to that, he held several leadership positions throughout his career including Chief Financial Officer at Teligent, Inc., a specialty generic pharmaceutical company, Fortovia Therapeutics Inc., a privately held healthcare company, Chief Financial Officer, Secretary and Treasurer of BioDelivery Sciences International, Inc., a public specialty pharmaceutical company and Chief Financial Officer of CorePharma LLC, a privately held specialty generic company.

    As CFO, Ernie will have responsibility for both finance and information technology.

    "I am pleased to be able to work with Ernie again as we look to grow this promising specialty development and manufacturing business. Ernie will bring his over thirty years of financial experience across a spectrum of pharmaceutical companies to help drive the growth of Corium Pharma Solutions. He will play an instrumental role working closely with myself, members of the leadership team, and our investors on our long-term growth strategy and its execution," said Mark Sirgo, CEO of CPSI, in making the announcement.

    Founded in 1995 in Grand Rapids, Michigan, Corium Pharma Solutions has maintained longstanding partnerships with multinational Fortune 500 companies and pharmaceutical businesses alike. CPSI currently manufactures a variety of over the counter and prescription products, including Proctor & Gamble Co's (NYSE:PG) entire Crest Whitestrips franchise, Agile Therapeutics, Inc.'s (NASDAQ:AGRX) Twirla®, and Corium, LLC's ("Corium") ADLARITY®, a once-weekly, transdermal donepezil patch.

    About Corium Pharma Solutions

    Headquartered in Grand Rapids, Michigan, Corium Pharma Solutions is a leading, full-service contract development and manufacturing organization specializing in novel drug and consumer product delivery technologies. With a track record spanning nearly 30 years, the company offers end-to-end solutions to its partners, from formulation and product development work, through commercial-scale manufacturing and packaging. The company's success is enabled by its state-of-the-art facilities, highly tenured operational leadership, and proprietary drug delivery technologies, CORPLEX™ and MICROCOR®. Corium Pharma Solutions is jointly owned by B-FLEXION and Webster Equity Partners. Prior to the CPSI transaction with Webster Equity Partners in October 2022, Gurnet Point Capital, an affiliate of B-Flexion, led the original investment in Corium Pharma Solutions through a take-private transaction in October 2018.

    About Gurnet Point Capital & B-FLEXION

    Gurnet Point Capital, an affiliate of B-FLEXION, is a leading healthcare fund that invests in de-risked life sciences companies. Gurnet Point primarily focuses on businesses that have high growth potential in the late product development and commercialization stages of their evolution. These companies become partners not just because of their capacity to generate economic value, but also because of their potential to deliver social impact. Gurnet Point's team of highly experienced industry executives works closely with its portfolio companies, with an active approach driving operational transformation and outsized returns.

    www.gurnetpointcapital.com/

    B-FLEXION is a private, entrepreneurial investment firm, partnering with sophisticated capital to meet the shared goal of delivering exceptional value over the generations, while also contributing positively to society. The company oversees growth-oriented operating businesses and asset managers, always with an 'active owner' philosophy. B-FLEXION invests across a wide range of industries, including healthcare. Gurnet Point Capital, an affiliate of B-FLEXION, leads B-FLEXION's de-risked life sciences investment strategy.

    https://www.bflexion.com/

    About Webster Equity Partners

    Founded in 2003, Webster is a private equity firm that focuses on high impact growth strategies that seek to deliver optimal outcomes for our investors, portfolio companies and the communities that we serve. Our mission is to deliver superior returns to our partners through the investment in and development of purpose driven patient-centric healthcare organizations dedicated to providing best of class clinical care and service to their patients. https://websterequitypartners.com/

    Contact

    Gartman PR

    (202) 413-4226

    Cision View original content:https://www.prnewswire.com/news-releases/corium-pharma-solutions-names-ernie-de-paolantonio-as-chief-financial-officer-301746886.html

    SOURCE Corium Pharma Solutions Inc.

    Get the next $AGRX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AGRX
    $PG

    CompanyDatePrice TargetRatingAnalyst
    Procter & Gamble Company
    $PG
    5/1/2025$161.00Buy → Neutral
    Redburn Atlantic
    Procter & Gamble Company
    $PG
    4/25/2025$177.00Sector Perform → Outperform
    RBC Capital Mkts
    Procter & Gamble Company
    $PG
    11/25/2024$160.00 → $209.00Neutral → Buy
    DA Davidson
    Procter & Gamble Company
    $PG
    10/10/2024$159.00Neutral
    DA Davidson
    Procter & Gamble Company
    $PG
    9/30/2024$163.00Overweight → Equal Weight
    Barclays
    Procter & Gamble Company
    $PG
    9/24/2024$174.00Neutral
    Piper Sandler
    Procter & Gamble Company
    $PG
    8/29/2024$190.00Hold → Buy
    DZ Bank
    Procter & Gamble Company
    $PG
    7/24/2024$182.00 → $175.00Buy → Hold
    Jefferies
    More analyst ratings

    $AGRX
    $PG
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Procter & Gamble downgraded by Redburn Atlantic with a new price target

      Redburn Atlantic downgraded Procter & Gamble from Buy to Neutral and set a new price target of $161.00

      5/1/25 7:44:23 AM ET
      $PG
      Package Goods/Cosmetics
      Consumer Discretionary
    • Procter & Gamble upgraded by RBC Capital Mkts with a new price target

      RBC Capital Mkts upgraded Procter & Gamble from Sector Perform to Outperform and set a new price target of $177.00

      4/25/25 8:25:38 AM ET
      $PG
      Package Goods/Cosmetics
      Consumer Discretionary
    • Procter & Gamble upgraded by DA Davidson with a new price target

      DA Davidson upgraded Procter & Gamble from Neutral to Buy and set a new price target of $209.00 from $160.00 previously

      11/25/24 7:49:48 AM ET
      $PG
      Package Goods/Cosmetics
      Consumer Discretionary

    $AGRX
    $PG
    SEC Filings

    See more
    • Procter & Gamble Company filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - PROCTER & GAMBLE Co (0000080424) (Filer)

      6/9/25 4:19:17 PM ET
      $PG
      Package Goods/Cosmetics
      Consumer Discretionary
    • Procter & Gamble Company filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - PROCTER & GAMBLE Co (0000080424) (Filer)

      6/5/25 6:03:25 AM ET
      $PG
      Package Goods/Cosmetics
      Consumer Discretionary
    • SEC Form 11-K filed by Procter & Gamble Company

      11-K - PROCTER & GAMBLE Co (0000080424) (Filer)

      5/30/25 10:32:18 AM ET
      $PG
      Package Goods/Cosmetics
      Consumer Discretionary

    $AGRX
    $PG
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • The Most Refreshing Drop of the Summer: Olay and Secret Debut Limited Edition Summer Fizz Scent Collection

      Seasonal body wash and antiperspirant deliver visible skin benefits and irresistible scents Olay and Secret, powerhouse brands from Procter & Gamble, are shaking up the season with the launch of the limited-edition Summer Fizz Scent collection featuring serum-infused body washes from Olay and clinical strength antiperspirants from Secret. Designed to deliver an invigorating burst of freshness, this collection features fruity scents and superior skin-delivery technology that nourishes skin and provides a sweet escape to make every day feel like a sun-soaked getaway. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250612475757/en

      6/12/25 8:08:00 AM ET
      $PG
      Package Goods/Cosmetics
      Consumer Discretionary
    • IFF Appoints Virginia "Gina" Drosos to Board of Directors

      IFF (NYSE:IFF)—a global leader in flavors, fragrances, food ingredients, health and biosciences—today announced the appointment of Gina Drosos to its board of directors, effective June 16. Drosos brings more than 30 years of executive leadership experience across the retail, consumer goods, beauty and health care industries. "We are very pleased to welcome Gina to the IFF board," said Kevin O'Byrne, chair of the board. "Gina brings extensive relevant experience, deep consumer insights and a proven ability to drive innovation and lead with purpose, which aligns with our long-term strategy to deliver sustainable growth and value creation for all stakeholders." Drosos most recently served

      6/9/25 5:46:00 PM ET
      $IFF
      $PG
      $SIG
      Major Chemicals
      Industrials
      Package Goods/Cosmetics
      Consumer Discretionary
    • P&G Appoints Craig Arnold to Board of Directors

      The Procter & Gamble Company (NYSE:PG) today announced the appointment of Craig Arnold, former Chairman and Chief Executive Officer of Eaton Corporation, to its Board of Directors, effective June 9, 2025. Mr. Arnold brings significant experience as a successful chief executive of a global enterprise serving businesses and customers in more than 175 countries. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250609584955/en/P&G Appoints Craig Arnold to Board of Directors With a distinguished career at Eaton, a global leader in power infrastructure and technology, Arnold led the company through transformative changes from 2016 to Ma

      6/9/25 4:15:00 PM ET
      $PG
      Package Goods/Cosmetics
      Consumer Discretionary